CINECA IRIS Institutional Research Information System

FESTUCCIA, MORENO BENEDETTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.259
EU - Europa 3.236
AS - Asia 1.667
SA - Sud America 183
AF - Africa 67
OC - Oceania 57
Continente sconosciuto - Info sul continente non disponibili 15
Totale 9.484
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.119
CN - Cina 844
IT - Italia 768
DE - Germania 641
FR - Francia 293
SE - Svezia 239
JP - Giappone 208
IE - Irlanda 204
AT - Austria 165
ES - Italia 164
GB - Regno Unito 164
SG - Singapore 132
FI - Finlandia 131
CA - Canada 104
TR - Turchia 94
KR - Corea 91
PL - Polonia 88
VN - Vietnam 74
UA - Ucraina 64
BR - Brasile 63
NL - Olanda 54
AU - Australia 50
IN - India 48
SN - Senegal 46
AR - Argentina 41
BE - Belgio 41
CO - Colombia 41
TW - Taiwan 36
RU - Federazione Russa 35
GR - Grecia 33
ID - Indonesia 29
MX - Messico 28
DK - Danimarca 26
HK - Hong Kong 26
CH - Svizzera 22
HU - Ungheria 22
TH - Thailandia 22
BY - Bielorussia 21
PE - Perù 21
IL - Israele 20
PT - Portogallo 18
CL - Cile 15
JO - Giordania 11
RO - Romania 11
CZ - Repubblica Ceca 8
EU - Europa 8
SI - Slovenia 8
UZ - Uzbekistan 8
ZA - Sudafrica 8
AP - ???statistics.table.value.countryCode.AP??? 7
IR - Iran 7
NZ - Nuova Zelanda 7
SA - Arabia Saudita 7
HR - Croazia 6
AZ - Azerbaigian 5
EG - Egitto 5
PA - Panama 3
RS - Serbia 3
TN - Tunisia 3
CR - Costa Rica 2
CU - Cuba 2
EC - Ecuador 2
KE - Kenya 2
MA - Marocco 2
PH - Filippine 2
PK - Pakistan 2
BG - Bulgaria 1
EE - Estonia 1
LT - Lituania 1
LV - Lettonia 1
MD - Moldavia 1
MY - Malesia 1
NO - Norvegia 1
PR - Porto Rico 1
SK - Slovacchia (Repubblica Slovacca) 1
TZ - Tanzania 1
Totale 9.484
Salva come PNG Salva come JPEG
Città #
Beijing 359
Fairfield 330
Chandler 291
Houston 219
Dublin 196
Wilmington 194
Ashburn 191
Torino 165
Woodbridge 159
Seattle 155
Redwood City 142
Vienna 141
Ann Arbor 137
Cambridge 124
Pisa 113
Dearborn 110
Singapore 110
Villeurbanne 103
Nyköping 93
Tokyo 80
New York 76
Warsaw 71
Shanghai 70
Medford 64
Princeton 62
Dong Ket 55
Jacksonville 51
Madrid 48
Florence 46
Milan 40
Munich 40
Guangzhou 36
Paris 33
Rome 28
Jakarta 27
Helsinki 26
Fremont 25
Nanjing 25
Toronto 25
Ankara 24
Hangzhou 23
Taipei 23
Duncan 22
Düsseldorf 22
London 22
San Mateo 22
Wuhan 22
Boston 21
Buenos Aires 21
Rochester 21
Chicago 20
Istanbul 20
Phoenix 20
San Diego 20
Zhengzhou 20
Hefei 19
Turin 18
Brussels 17
Lima 17
Nürnberg 17
Bogotá 16
Los Angeles 15
Santa Clara 15
Bologna 14
Chengdu 14
Nanning 14
Ottawa 14
Athens 13
Boardman 13
Changsha 13
Faenza 13
Philadelphia 13
Saint Louis 13
Seoul 13
Xian 13
Brescia 12
Budapest 12
Columbus 12
Salt Lake City 12
Tianjin 12
Denver 11
Leipzig 11
Osaka 11
Sydney 11
São Paulo 11
Baltimore 10
Essen 10
Fuzhou 10
Santiago 10
Valencia 10
Barcelona 9
Birmingham 9
Brooklyn 9
Buffalo 9
Cleveland 9
Frankfurt am Main 9
Leawood 9
Minneapolis 9
San Francisco 9
Amman 8
Totale 5.151
Salva come PNG Salva come JPEG
Nome #
Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation 2.711
Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs. 485
Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors 449
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) 419
Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation 393
Extracellular vesicles as potential biomarkers of acute graft-vs.-host-disease 282
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma 253
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma 252
CLINICAL IMPACT OF IMMUNOPHENOTYPIC REMISSION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN MULTIPLE MYELOMA 228
Prospective molecular monitoring of minimal residual disease after nonmyeloablative allografting in newly diagnosed multiple myeloma 194
Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation. 157
Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability. 150
null 148
A POST-REMISSION MAINTENANCE TREATMENT WITH LOW-DOSE CHEMOTHERAPY + RETINOIDS AND DIHYDROXYLATED VITAMIN D3 MAY IMPROVE THE SURVIVAL OF POOR-PROGNOSIS AML/MDS PATIENTS 148
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the italian bone marrow donor registry. 143
Late-Onset Hepatic Veno-Occlusive Disease after Allografting: Report of Two Cases with Atypical Clinical Features Successfully Treated with Defibrotide 137
THYMIC FUNCTION AND EARLY T CELL RECONSTITUTION AFTER HAPLOIDENTICAL MARROW TRANSPLANTATION 135
Restoring natural killer cell immunity against multiple myeloma in the era of new drugs 135
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. 135
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 124
Trichoderma species fungemia after high-dose chemotherapy and autologous stem cell transplantation: a case report 122
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 114
Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma 113
IMMUNOPHENOTYPIC RESPONSE AFTER ALLOGRAFTING IN MULTIPLE MYELOMA 112
Current use and potential role of procalcitonin in the diagnostic work up and follow up of febrile neutropenia in hematological patients 112
IMMUNOPHENOTYPIC REMISSION AFTER ALLOGRAFTING IN MULTIPLE MYELOMA 107
Haplo-identical allografting with post-transplant cyclophosphamide in high-risk patients 105
Is there a role for allografting in myeloma ?: an update of a comparative study 104
IMMUNOPHENOTYPIC RESPONSE AFTER ALLOGRAFTING IN MULTIPLE MYELOMA 102
Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma 101
ROLE OF ALLOGRAFTING IN HIGH RISK ACUTE MYELOID LEUKEMIA 97
TREATMENT OF POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) HAEMORRHAGIC CYSTITIS WITH INTRAVESCICAL HYALURONIC ACID 93
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 87
Recurrent plasmacytomas after allografting in a patient with multiple myeloma. 85
RECONSTITUTION OF THE T CELL COMPARTMENT AND THE THYMIC FUNCTION AFTER REDUCED-INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION 85
ROLE OF ALLOGRAFTING IN ACUTE LYMPHOBLASTIC LEUKEMIA: A 12 YEAR EXPERIENCE 84
Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation 79
Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting 75
Allografting in relapsed/refractory Hodgkin's lymphoma, a single-centre experience 70
A SALVAGE TREATMENT CONTAINING NOVEL AGENTS CONSOLIDATED BY ALLOGENEIC STEM CELL TRANSPLANTATION WITH REDUCED-INTENSITY CONDITIONING IMPROVES OUTCOME OF MULTIPLE MYELOMA PATIENTS FAILING AUTOLOGOUS TRANSPLANTATION 70
LONG TERM FOLLOW UP OF A COMPARISON OF NONMYELOABLATIVE ALLOGRAFTING WITH AUTOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA 69
Disease and Comorbidity Status Predict Outcome after Nonmyeloablative Allografting for Advanced Haematological Malignancies. 64
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents. 63
Induction with New Drugs and Planned Autologous Followed by Non-Myeloablative Allogeneic Transplantation in Newly Diagnosed Myeloma. 58
Total lymphoid irradiation and antithymocyte globulin to reduce graft-versus-host disease after allografting in haematological malignancies: a GITMO experience 57
Prognostic factors and outcome of reduced-intensity conditioning followed by allogeneic stem cell transplantation in patients with multiple myeloma relapsed after autografting and rescued with new drugs 56
Efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation at risk of hepatis B virus reactivation 55
Long-term follow-up of a comparison of non-myeloablative allografting with autografting for newly diagnosed myeloma 55
Role of Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation In Patients with Multiple Myeloma Relapsing After Autograft: a Donor Versus No Donor Analysis 54
Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation 50
Risk of hepatitis B and efficacy of treatment with lamivudine in patients undergoing allo-SCT 47
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? 44
Salvage treatment for relapsed/refractory hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents 42
Immune Reconstitution and Thymic Function After Reduced Intensity Allogeneic Hematopoietic Cell Transplantation 29
Totale 9.738
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.329
article - articoli 0
book - libri 0
conference - conferenze 6.667
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.996
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.272 0 0 75 193 139 183 154 119 131 96 103 79
2020/20211.280 113 73 99 77 111 102 121 102 111 98 117 156
2021/20221.022 65 60 60 108 56 38 87 68 49 87 203 141
2022/20231.228 88 124 58 111 91 252 84 85 122 70 71 72
2023/2024765 97 158 49 51 76 116 44 43 12 30 31 58
2024/2025196 18 96 82 0 0 0 0 0 0 0 0 0
Totale 9.738